Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.
Chronic Myeloid Leukemia
DRUG: Imatinib
major molecular response, the rate of major molecular response in two years, 2 years
complete cytogenetics response, the rate of complete cytogenetics response in one years, 1 years|over survival, the rate of over survival in two years, 2 years|progress free survival, the rate of progress free survival in two years, 2 years
This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.